Research Progress on Ultra-High-Speed Laser Cladding Technology and Its Coating Wear Resistance
Academic Journal of Emerging Technologies · 2025
DOI: 10.63313/ajet.2002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academic Journal of Emerging Technologies, 2025. Verfasst von Jing Li und 1 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ultra-high-speed laser cladding is an advanced surface coating method, which is widely used due to its characteristics of fast processing speed, small heat-affected zone, dense formed coating, and adaptability to multiple materials. This paper first briefly introduces the characteristics and advantages of ul-tra-high-speed laser cladding compared to traditional laser cladding technology, analyzes the processing principles of ultra-high-speed laser cladding technology, and combines the latest research to analyze the unique characteristics of ul-tra-high-speed laser cladding technology. Furthermore, the wear resistance of the coating produced by ultra-high-speed laser cladding technology is analyzed, and finally, based on the current research status at home and abroad, the short-comings of ultra-high-speed laser cladding technology are discussed, and the development trend of ultra-high-speed laser cladding technology is proposed.
Zitieren
APA
Li, J., & Yang, F. (2025). Research Progress on Ultra-High-Speed Laser Cladding Technology and Its Coating Wear Resistance. Academic Journal of Emerging Technologies. https://doi.org/10.63313/ajet.2002
Vancouver
Li J, Yang F. Research Progress on Ultra-High-Speed Laser Cladding Technology and Its Coating Wear Resistance. Academic Journal of Emerging Technologies. 2025. doi:10.63313/ajet.2002
BibTeX
@article{Li2025,
author = {Li, Jing and Yang, Fazhan},
title = {Research Progress on Ultra-High-Speed Laser Cladding Technology and Its Coating Wear Resistance},
journal = {Academic Journal of Emerging Technologies},
year = {2025},
doi = {10.63313/ajet.2002}
}
EUVIMED